Abstract
In the last few years several new agents for the treatment of acute leukemia have been studied. These have included amsacrine, idarubicin, mitoxantrone, homoharringtonine and most recently diaziquone [1]. Mitoxantrone is a relatively new synthetic anthracenedione derivative with strong antineoplastic activity in vitro and in vivo against solid tumors and leukemias [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arlin ZA (1990) Current status of mitoxantrone combination chemotherapy programs: a personal view. Leukemia Lymphoma 1: 301–305
Durr FE, Wallace RE, Citarella RV (1983) Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 10 [Suppl B]: 3–11
Rozmyslowicz T, Palynyczko G, Mazur J, Konopka L (1991) Mitoxantrone in the treatment of malignant haematological disorders (in Polish). Terapia i Leki 10: 255–262
Dalton WS, Cress AE, Alberts DS (1988) Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48: 1882–1888
Alberts DS, Peng Y-P, Leigh S et al. (1983) Disposition of mitoxantrone in patients. Cancer Treat Rev 10 [Suppl B]: 23–27
Benjamin RS, Chawla SP, Ewer MS et al. (1985) Evaluation of mitoxantrone cardiotoxicity by nuclear angiography and endomyocardial biopsy: an update. Invest New Drugs 3: 117–121
Arlin ZA, Silver R, Cassileth Pet al. (1985) Phase I—II trial of mitoxantrone in acute leukaemia. Cancer Treat Rep 69: 61–64
Arlin ZA, Dukart G, Schoch I et al. (1985) Phase I—II trial of mitoxantrone in acute leukemia: interim report. Invest New drugs 3: 213–217
Paciucci P, Dutcher J, Cuttner J et al. (1987) Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1 (7): 565–567
Hiddemann W, Kreutzmann H, Straif K et al. (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute leukemia. Blood 69: 744–749
Rozmyslowicz T, Palynyczko G, Mazur J et al. (1990) Mitoxantrone in treatment of refractory acute leukemias. Blood 76 (10) [Suppl 1]: 315a
Arlin ZA, Case D, Moore J et al. (1988) Randomized trial of mitoxantrone and daunorubicin-based therapy in untreated acute myelogenous leukemia. Am Soc Clin Oncol 7: 186
Hiddemann W, Büchner T, Heil G et al. (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 4 (9): 637–640
Kantarijan HM, Walters RL, Keating MJ et al. (1990) Mitoxantrone and high-dose arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65: 5–8
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Rozmyslowicz, T. et al. (1992). Treatment of Refractory and Relapsed Acute Leukemias with Cytosine Arabinoside and Mitoxantrone. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_72
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_72
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive